Larimar Therapeutics, Inc. — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 12/100
What the filing says
Form 8-K filed 2026-09-29 discloses Item 5.02 events (director/officer departure or appointment and compensatory arrangements), but the filing document provided contains only metadata and document structure—no substantive details about counterparties, amounts, names, dates, or specific changes are visible in the text supplied.
Why this rating
Insufficient disclosure detail in provided text; routine periodic officer/compensation reporting; no material financial amounts or strategic changes quantified.
Extracted items
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.